BergerJR.Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord2017; 12: 59–63.
2.
AoyamaSMoriMUzawaA, et al. Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: Elevations along with fingolimod treatment duration. J Neurol2018; 265: 1145–1150.
3.
KimSHHyunJWJeongIH, et al. Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder. J Neurol2015; 262: 696–700.
4.
WingerchukDMBanwellBBennettJL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology2015; 85: 177–179.
5.
BozicCSubramanyamMRichmanS, et al. Anti-JC virus (JCV) antibody prevalence in the JCV epidemiology in MS (JEMS) trial. Eur J Neurol2014; 21: 299–304.
